Users online: 2963    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2019, Volume : 12, Issue : 11
First page : ( 5223) Last page : ( 5230)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2019.00904.1

Formulation and Comparative Evaluation of Etoricoxib Loaded Osmotic Drug Delivery Systems

Muthukumar S.1,*, Sankar C.1, kumaran G. Arul1, Shalini S.2, Vinesha R1, Varghese Shalumol1

1Department of Pharmaceutics, KMCH College of Pharmacy, Coimbatore, Tamil Nadu, India. (Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai)

2Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore, Tamil Nadu, India. (Affiliated to The Tamil Nadu Dr. M.G.R. Medical University, Chennai)

*Corresponding Author E-mail: pharmmuthu@gmail.com

Online published on 9 April, 2020.


Osmotic drug delivery systems are gaining interest as they deliver the drug based on the principle of osmosis. Osmosis is defined as the spontaneous movement of solvent from a solution of lower solute concentration to a solution of higher solute concentration through a semipermeable membrane Aim of this study was to formulate and evaluate oral osmotic drug delivery systems of Etoricoxib for the treatment of inflammation and arthritis. A single compartment system (tablet) and a multi-compartment system (capsule) have been prepared. The granules for the osmotic tablet were prepared by wet granulation technique using PVP K 30 in ethanol as binder. The granules were evaluated for its flow property and the tablets were compressed and coated. Then the osmotic capsules of Etoricoxib was prepared and coated. A micro orifice was drilled for the capsule. Both the tablets and capsules were evaluated and the best formulation was determined. The release studies showed that F1 formulation (osmotic tablet) which contained equal proportion of mannitol and lactose as osmogens showed a maximum release of 68.56% and was the most promising among the 6 formulations. The kinetic analysis was done for F1. The formulation was found to be stable at an accelerated temperature of 40° ± 2°C, RH 70% ± 5% for 45 days.



Osmotic drug delivery system, Etoricoxib, osmosis, inflammation, arthritis.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
514,063,709 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.